Pharmaceutical

AstraZeneca plots new 96,000 sq ft Macclesfield facility

Updated on Wednesday 4 December 2019, 3:49 PM

1 Minute Read

The pharmaceutical firm’s plans for Building 52, a 96,000 sq ft manufacturing facility on Hurdsfield Industrial Estate in Macclesfield, has been recommended for approval at Cheshire East’s planning committee next week.

The site off Hulley Road and the A523 previously held temporary portakabins and a single-storey steel framed workshop which have since been dismantled and removed. It is subject to a planning application for remediation works, which if approved, would lower the hill site level to the surrounding ground level and prepare the site for redevelopment.

The two-storey building will enable Astrazeneca to hire 72 employees to join the 1,800 people already employed at the site. It also forms part of the wider Hurdsfield Industrial Estate identified as a key employment site in the Cheshire East Local Plan Strategy.

According to the planner Frost Planning: “This proposal as a new pharmaceutical manufacturing facility represents potential significant investment in the Macclesfield Campus. The manufacture of prescription medicines is a highly technical and complex process that requires a high degree of sophistication in both the equipment used in the manufacturing process and in the production building themselves.

“Building 52 is designed to meet current and future regulatory requirements and it will be able to supply pharmaceutical formulation to the worldwide market for the next 20 years.”

Press Kit

To obtain a copy of our press kit, please message us using the adjacent contact form.

Contact

Thank you, we will be in contact shortly.

AMRC Sheffield
Boeing
Bott
University of Wolves Racing
Mach Exhibition

Are you enjoying this article?

Sign up to our email newsletter and don't miss out on more articles like this.

* indicates required

Do you give consent for MTDMFG to send you communications?

You can unsubscribe at any time by clicking the link in the footer of our emails.